Join us for a KOL Event with OKYO Pharma, featuring Pedram Hamrah, MD (Tufts University School of Medicine) who will discuss the current treatment landscape for patients suffering from Dry Eye Disease (DED) and the potential of OKYO’s OK-101 drug candidate for treating patients with this chronic disease.

OKYO Pharma’s leadership team will provide a company update along with insight into its Phase 2 plans for OK-101. OK-101 is a novel lipid-conjugated peptide analog (developed using a membrane-anchored peptide technology) that targets a key ocular receptor found to show both anti-inflammatory and corneal neuropathic pain reducing activities, two major symptoms underserved by current dry eye therapies.

A live Q&A session will follow the formal presentations.